A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy)

Autor: Ann Verhaegen, Olivier Van Caenegem, Raymond Kacenelenbogen, Michel Guillaume, Fabian Demeure, Caroline Wallemacq, Olivier Vanakker, Anna A.H. Mertens, Michel Hermans, Antoine Bondue, Anne De Leener, Stephane Carlier, Walter Desmet, Pieter Vermeersch, Ernst Rietzschel, Ivan Elegeert, Fabien Chenot, Jean-Louis Vanoverschelde, Emilie Castermans, Christophe Beauloye, Olivier S. Descamps, Antoine De Meester, E. Hoffer, Christophe De Block, Marc J. Claeys, Jean-Luc Balligand, Nicolas Paquot, Attilio Leone, Michel Langlois, Herbert De Raedt, Patrizio Lancellotti
Přispěvatelé: BAS, BSC, RBSLM, Clinical sciences, Vrije Universiteit Brussel, Faculty of Arts and Philosophy, UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de pathologies cardiovasculaires intensives, UCL - (SLuc) Service de soins intensifs, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Centre de génétique médicale UCL, UCL - (MGD) Service de cardiologie
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Cardiac & Cardiovascular Systems
Cardiologie et circulation
IMPACT
CHILDREN
Disease
030204 cardiovascular system & hematology
Workflow
0302 clinical medicine
Belgium
Risk Factors
Prevalence
CRITERIA
030212 general & internal medicine
Myocardial infarction
CARDIOLOGY
education.field_of_study
Autosomal dominant lipoprotein disorder
Prognosis
Cardiovascular disease
Phenotype
Cardiovascular Diseases
Critical Pathways
Lipoprotein disorder
Cardiology and Cardiovascular Medicine
Familial hypercholesterolaemia
Life Sciences & Biomedicine
Algorithms
Genetic Markers
Coronary care unit
medicine.medical_specialty
Consensus
Clinical Decision-Making
Population
Cascade screening
DIAGNOSIS
Risk Assessment
Significant elevation
Decision Support Techniques
Hyperlipoproteinemia Type II
03 medical and health sciences
Predictive Value of Tests
EUROPEAN ATHEROSCLEROSIS SOCIETY
medicine
MANAGEMENT
Humans
Genetic Predisposition to Disease
Low-density lipoprotein cholesterol
Intensive care medicine
education
Alirocumab
Science & Technology
business.industry
Coronary Care Units
ALIROCUMAB
Cholesterol
LDL
medicine.disease
Peripheral Vascular Disease
MYOCARDIAL-INFARCTION
Mutation
Cardiovascular System & Cardiology
Human medicine
business
Biomarkers
GENETIC-DEFECTS
Zdroj: Atherosclerosis
Atherosclerosis, 277
Atherosclerosis, Vol. 277, p. 369-376 (2018)
ISSN: 0021-9150
Popis: Background and aims: Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein disorder characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly increased risk of premature cardiovascular disease (CVD). Because of the very high coronary artery disease risk associated with this condition, the prevalence of FH among patients admitted for CVD outmatches many times the prevalence in the general population. Awareness of this disease is crucial for recognizing FH in the aftermath of a hospitalization of a patient with CVD, and also represents a unique opportunity to identify relatives of the index patient, who are unaware they have FH. This article aims to describe a feasible strategy to facilitate the detection and management of FH among patients hospitalized for CVD. Methods: A multidisciplinary national panel of lipidologists, cardiologists, endocrinologists and cardio-geneticists developed a three-step diagnostic algorithm, each step including three key aspects of diagnosis, treatment and family care. Results: A sequence of tasks was generated, starting with the process of suspecting FH amongst affected patients admitted for CVD, treating them to LDL-C target, finally culminating in extensive cascade-screening for FH in their family. Conceptually, the pathway is broken down into 3 phases to provide the treating physicians with a time-efficient chain of priorities. Conclusions: We emphasize the need for optimal collaboration between the various actors, starting with a “vigilant doctor” who actively develops the capability or framework to recognize potential FH patients, continuing with an “FH specialist” and finally involving the patient himself as ”FH ambassador” to approach his/her family and facilitate cascade screening and subsequent treatment of relatives.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: